Sun Pharma Advanced Research Company Limited has informed the Exchange regarding a press release dated December 02, 2025, titled "Press Release about U.S. District Court Grants Summary Judgement in Favour of SPARC for Sezaby PRV".
SPARC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
SPARC has informed the stock exchange that a U.S. District Court has granted a summary judgement in the company's favour in a legal matter connected to the Priority Review Voucher (PRV) linked to its drug Sezaby. A PRV is a valuable certificate issued by the U.S. FDA when a drug treating a rare pediatric disease is approved, and it can be used to fast-track the review of another drug or sold to other companies, often for large sums. A summary judgement means the court decided SPARC's side of the case is strong enough to win without needing a full trial. SPARC has not disclosed the exact financial value or the identity of the opposing party in the brief filing.
This ruling is positive for SPARC shareholders as it clears legal uncertainty around the ownership of the Sezaby PRV, which could be a significant asset. Retaining or monetising the PRV could add meaningful upside to SPARC's standalone valuation beyond its drug pipeline.